...
首页> 外文期刊>International journal of clinical oncology >Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma
【24h】

Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma

机译:甲状腺乳头状癌侵袭性变体中碘化钠同向表达的低表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background A decreased radioiodine uptake is associated with high recurrence rate and reduced survival in papillary thyroid carcinoma (PTC). Sodium iodide symporter (NIS) expression status in aggressive PTC variants is unknown. Methods NIS expression in conventional PTC and aggressive PTC variants such as tall cell variant (TCV) and diffuse sclerosing variant (DSPTC) was investigated using immunohistochemical detection. Results Patients having TCV and DSPTC were significantly more likely to have extrathyroidal extension and lymph nodes metastases (P < 0.05). Positive NIS staining was identified in 228 of 312 (73.1 %) patients with conventional PTC, 9 of 28 (32.1 %) patients with TCV and 12 of 30 (40.0 %) patients with DSPTC. NIS expression distinguished conventional PTC from TCV and DSPTC significantly (P < 0.01). Conclusion Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis.
机译:背景放射性碘摄入减少与甲状腺乳头状癌(PTC)的高复发率和生存期降低相关。侵略性PTC变体中的碘化钠共转运蛋白(NIS)表达状态未知。方法使用免疫组织化学检测方法研究NIS在常规PTC和侵袭性PTC变体(例如高细胞变体(TCV)和弥散性硬化变体(DSPTC))中的表达。结果TCV和DSPTC的患者更有可能发生甲状腺外扩张和淋巴结转移(P <0.05)。在312例常规PTC患者中,有228例(73.1%),28例TCV患者中的9例(32.1%)和30例DSPTC患者中的12例(40.0%)中发现了NIS阳性。 NIS表达将传统PTC与TCV和DSPTC显着区分开(P <0.01)。结论TCV和DSPTC由于其NIS低表达,需要更高剂量的放射性碘治疗累积剂量以改善其预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号